NO20011132D0 - FremgangsmÕte til Õ innføre apoptosis i kreftceller - Google Patents

FremgangsmÕte til Õ innføre apoptosis i kreftceller

Info

Publication number
NO20011132D0
NO20011132D0 NO20011132A NO20011132A NO20011132D0 NO 20011132 D0 NO20011132 D0 NO 20011132D0 NO 20011132 A NO20011132 A NO 20011132A NO 20011132 A NO20011132 A NO 20011132A NO 20011132 D0 NO20011132 D0 NO 20011132D0
Authority
NO
Norway
Prior art keywords
procedure
cancer cells
apoptosis
introducing
introducing apoptosis
Prior art date
Application number
NO20011132A
Other languages
English (en)
Other versions
NO20011132L (no
Inventor
David Tsai
Jenny Yu
Original Assignee
David Tsai
Jenny Yu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David Tsai, Jenny Yu filed Critical David Tsai
Publication of NO20011132D0 publication Critical patent/NO20011132D0/no
Publication of NO20011132L publication Critical patent/NO20011132L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20011132A 1998-09-08 2001-03-06 Fremgangsmåte til å innföre apoptosis i kreftceller NO20011132L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/149,878 US5994298A (en) 1997-12-18 1998-09-08 Proteins for cancer cell specific induction of apoptosis and method for isolation thereof
PCT/US1999/020677 WO2000013700A1 (en) 1998-09-08 1999-09-08 Method of using fetuin to induce apoptosis in cancer cells

Publications (2)

Publication Number Publication Date
NO20011132D0 true NO20011132D0 (no) 2001-03-06
NO20011132L NO20011132L (no) 2001-05-03

Family

ID=22532177

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011132A NO20011132L (no) 1998-09-08 2001-03-06 Fremgangsmåte til å innföre apoptosis i kreftceller

Country Status (10)

Country Link
US (1) US5994298A (no)
EP (1) EP1119367A4 (no)
AU (1) AU5914799A (no)
CA (1) CA2345050A1 (no)
IL (1) IL141876A0 (no)
MX (1) MXPA01002398A (no)
NO (1) NO20011132L (no)
NZ (1) NZ510947A (no)
TW (1) TW593335B (no)
WO (1) WO2000013700A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238662B2 (en) * 1997-12-18 2007-07-03 Ambryx Biotechnology, Inc. Alpha 2HS glycoprotein for treatment of cancer and a method for preparation thereof
US6737402B2 (en) * 1997-12-18 2004-05-18 David Tsai Method of preparing fetuin to induce apoptosis
US6258779B1 (en) * 1997-12-18 2001-07-10 David Tsai Method of using fetuin to induce apoptosis in cancer cells
AU3365800A (en) * 1999-02-16 2000-09-04 Board Of Trustees Of The Leland Stanford Junior University Combined therapy of diterpenoid triepoxides and trail for synergistic killing oftumor cells
US6329148B1 (en) 1999-02-16 2001-12-11 The Board Of Trustees Of The Leland Stanford University Combined therapy of diterpenoid triepoxides and death domain receptor ligands for synergistic killing of tumor cells
JP2003502282A (ja) * 1999-04-08 2003-01-21 ザ ゼネラル ホスピタル コーポレーション ヒト転移性細胞の作用因子源から離れた意図された移動
US6900185B1 (en) 2000-04-12 2005-05-31 University Of Iowa Research Foundation Method of inducing tumor cell apoptosis using trail/Apo-2 ligand gene transfer
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
CA2355334A1 (en) * 2000-10-16 2002-04-16 Procyon Biopharma Inc. Pharmaceutical preparations and methods for inhibiting tumors
US20030044400A1 (en) * 2001-05-22 2003-03-06 Jenny Yu Composition and method for treating cells
US20050026833A1 (en) * 2001-11-08 2005-02-03 Rabbani Shafaat Ahmed PSP-94: use for treatment of hypercalcemia and bone metastasis
CA2509193A1 (en) * 2002-12-06 2004-06-24 The General Hospital Corporation Methods and compositions relating to gradient exposed cells
US7232893B2 (en) * 2003-07-12 2007-06-19 Saint Louis University Method of manufacturing a stellate cell death factor
US20060275838A1 (en) * 2003-07-12 2006-12-07 Ranjit Ray Compositions and methods for inhibiting liver stellate cell growth
US20050148514A1 (en) * 2003-09-26 2005-07-07 Panchal Chandra J. Method and composition for treatment of angiogenesis
CA2441695A1 (en) * 2003-09-26 2005-03-26 Unknown Regulation of matrix metalloproteinases by psp94 family members
US9789171B2 (en) 2004-11-05 2017-10-17 The General Hospital Corporation Anti-fugetactic agents for the treatment of ovarian cancer
US7528108B2 (en) * 2005-04-26 2009-05-05 Ambryx Biotechnology, Inc. Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments
WO2009034562A2 (en) * 2007-09-11 2009-03-19 Dublin City University A method of assessing lung squamous cell carcinoma status in an individual
US20100022442A1 (en) 2008-07-25 2010-01-28 Ambryx Biotechnology, Inc. Compositions and methods for increasing serum antioxidant concentrations, decreasing serum triglyceride levels, inhibiting insulin-receptor signaling activity, increasing serum ghrelin levels, and decreasing serum tnf-alpha levels
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002651A2 (en) * 1984-10-23 1986-05-09 Max-Planck-Gesellschaft Zur Förderung Der Wissensc Specific carbohydrate-binding proteins (lectins) of mammalian tumor cells
US5449757A (en) * 1990-06-01 1995-09-12 W. Alton Jones Cell Science Center Mammalian adipogenic factors
ES2157981T3 (es) * 1993-03-12 2001-09-01 Xoma Technology Ltd Usos terapeuticos de productos proteicos bactericidas/aumentadores de la permeabilidad.
US5902582A (en) * 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
AU1586997A (en) * 1996-02-20 1997-09-10 Inka Brockhausen Human serum lectin - induced apoptosis and method for detecting apoptosis
US6011005A (en) * 1997-09-18 2000-01-04 The Picower Institute For Medical Research Prevention of pregnancy miscarriages

Also Published As

Publication number Publication date
MXPA01002398A (es) 2003-03-10
IL141876A0 (en) 2002-03-10
US5994298A (en) 1999-11-30
AU5914799A (en) 2000-03-27
EP1119367A1 (en) 2001-08-01
WO2000013700A1 (en) 2000-03-16
TW593335B (en) 2004-06-21
CA2345050A1 (en) 2000-03-16
NO20011132L (no) 2001-05-03
EP1119367A4 (en) 2002-07-24
NZ510947A (en) 2003-08-29

Similar Documents

Publication Publication Date Title
NO20011132D0 (no) FremgangsmÕte til Õ innføre apoptosis i kreftceller
DK1165078T3 (da) Fremgangsmåder til induktion af cancercelledöd og tumorregression
NO20004451D0 (no) FremgangsmÕte for Õ utføre telling av blodceller
ZA992005B (en) Proton donating actives in absorbent articles.
MXPA02001866A (es) Cateter de drenaje lumbar.
ITMI990375A1 (it) Trattamento del cancro co epotiloni
ID28217A (id) Rakitan pengunci untuk panel-panel
NO991691D0 (no) Cancer-immunoterapi ved Õ bruke tumorceller kombinert med blandede lymfocytter
DE19980447D2 (de) Solarzellenanordnung
EP1076568A4 (en) NON-INVASIVE PROCEDURE FOR DETECTING PROSTATE CANCER
ID17088A (id) Tablet galantamin hidrobromida yang sangat mudah larut
DE69941616D1 (de) Solarzelle
DE69907918D1 (de) Solarzellen-BAUELEMENT
DK0942754T3 (da) Konjugater anvendelige til behandlingen af prostatacancer
NO974972L (no) FremgangsmÕte for Õ hindre brystcancer
NO20004187D0 (no) FremgangsmÕte for Õ behandle prosessvann
NO20031531D0 (no) Fremgangsmåter for reduksjon av kreftcelledöd og tumorregresjon
PT1077976E (pt) Azois soluveis em agua como antifungicos de largo espectro
MA24838A1 (fr) Serre
DE10195284D2 (de) Reformeranlage mit Wärmeschild
IS5502A (is) Samtengd efnasambönd nytsamleg við meðhöndlun á krabbameini í blöðruhálskirtli
HUP0104568A3 (en) Human prostatic cell lines for cancer treatment
NO981818D0 (no) FremgangsmÕte for Õ mobilisere hematopoetiske stamceller
NO20006635D0 (no) Langrennsski egnet for sköyteteknikk
DE59910093D1 (de) Hydraulisch betätigter Drehsteller

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application